<DOC>
	<DOCNO>NCT02108015</DOCNO>
	<brief_summary>Objective Ionotropic glutamate receptor ligand-gated ion channel responsible excitatory neurotransmission mammalian central nervous system ( CNS ) . Based pharmacology , group three subtypes-NMDA , AMPA kainate . In recent year become apparent receptor function alone , company auxiliary protein regulate activity [ 1 ] . Some show modulate AMPA receptor trafficking , gate pharmacology classify transmembrane AMPA receptor regulatory protein , TARPs ( &gt; =-2 , &gt; =-3 , &gt; =-4 , &gt; =-5 , &gt; =-7 , &gt; =-8 ) . Genetic data indicate possible role TARPs schizophrenia , depression , epilepsy , neuropathic pain , bipolar disorder [ 1 ] . In preclinical collaboration Eli Lilly , develop promising radioligand , 18F-TARP252 image TARP &gt; =-8 use positron emission tomography ( PET ) . This protocol cover three phase : - Phase 1 : kinetic brain image quantify TARP &gt; =-8 brain relative concurrent measurement parent radioligand arterial plasma ; - Phase 2 : 18F-TARP252 successful Phase 1 , estimate radiation-absorbed dos perform whole body imaging ; - Phase 3 : test-retest analysis brain bind relative concurrent measurement parent radioligand arterial plasma . Study Population Healthy adult female male volunteer ( n=22 , age 18 - 55 ) undergo brain imaging . An additional eight healthy volunteer undergo whole body dosimetry analysis . Design For quantification TARP &gt; =-8 , 22 healthy control brain PET image use 18F-TARP252 arterial line . Some test-retest scan . Eight additional subject whole body PET scan dosimetry . For dosimetry , arterial line use . Outcome Measures To assess quantitation TARP &gt; =-8 18F-TARP252 , primarily use two outcome measure : identifiability time stability distribution volume calculate compartmental modeling . In test-retest study , calculate retest variability . We assess whole-body biodistribution dosimetry 18F-TARP252 calculating dos organ effective dose body .</brief_summary>
	<brief_title>Evaluation Novel Positron Emission Tomography ( PET Radiotracer TARP Gamma-8</brief_title>
	<detailed_description>Objective Ionotropic glutamate receptor ligand-gated ion channel responsible excitatory neurotransmission mammalian central nervous system ( CNS ) . Based pharmacology , group three subtypes-NMDA , AMPA kainate . In recent year become apparent receptor function alone , company auxiliary protein regulate activity [ 1 ] . Some show modulate AMPA receptor trafficking , gate pharmacology classify transmembrane AMPA receptor regulatory protein , TARPs ( &gt; =-2 , &gt; =-3 , &gt; =-4 , &gt; =-5 , &gt; =-7 , &gt; =-8 ) . Genetic data indicate possible role TARPs schizophrenia , depression , epilepsy , neuropathic pain , bipolar disorder [ 1 ] . In preclinical collaboration Eli Lilly , develop promising radioligand , 18F-TARP252 image TARP &gt; =-8 use positron emission tomography ( PET ) . This protocol cover three phase : - Phase 1 : kinetic brain image quantify TARP &gt; =-8 brain relative concurrent measurement parent radioligand arterial plasma ; - Phase 2 : 18F-TARP252 successful Phase 1 , estimate radiation-absorbed dos perform whole body imaging ; - Phase 3 : test-retest analysis brain bind relative concurrent measurement parent radioligand arterial plasma . Study Population Healthy adult female male volunteer ( n=22 , age 18 - 55 ) undergo brain imaging . An additional eight healthy volunteer undergo whole body dosimetry analysis . Design For quantification TARP &gt; =-8 , 22 healthy control brain PET image use 18F-TARP252 arterial line . Some test-retest scan . Eight additional subject whole body PET scan dosimetry . For dosimetry , arterial line use . Outcome Measures To assess quantitation TARP &gt; =-8 18F-TARP252 , primarily use two outcome measure : identifiability time stability distribution volume calculate compartmental modeling . In test-retest study , calculate retest variability . We assess whole-body biodistribution dosimetry 18F-TARP252 calculating dos organ effective dose body .</detailed_description>
	<criteria>INCLUSION CRITERIA : Age 18 55 ( include 18 55 ) . Able give write informed consent . Healthy Enrolled 01M0254 EXCLUSION CRITERIA : Any current Axis I diagnosis . Clinically significant laboratory abnormality . Positive HIV test . Unable MRI scan . History neurologic illness injury potential affect study data interpretation . Recent exposure radiation relate research ( i.e . PET research ) , combine study , would allowable limit . Inability lie flat camera bed least two hour . Pregnancy breast feed . Able get pregnant use birth control . Drug/alcohol abuse dependence Exclusion criterion dosimetry subject report , exception MRI contraindication , MRI perform subject .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Transmembrane AMPA Receptor Regulatory Protein</keyword>
	<keyword>Glutamate Receptors</keyword>
	<keyword>Healthy Volunteers</keyword>
</DOC>